Biology's Arnold Caplan weighs in on whether FDA should review stem-cell treatments
MEDIA |
September 13, 2016 STORY BY:
EDITORIAL STAFF
Nature: Biology Professor Arnold Caplan weighed in on the debate over whether the Federal Drug Administration should review stem-cell treatments conducted by clinics.
